Patient baseline and disease characteristics
| . | Arm T Tafasitamab + R-CHOP (n = 33) . | Arm T/L Tafasitamab + lenalidomide + R-CHOP (n = 33) . | Overall (n = 66) . |
|---|---|---|---|
| Median age (range), y | 66.0 (43-86) | 64.0 (20-79) | 64.5 (20-86) |
| Age categories (y), n (%) | |||
| ≤60 | 12 (36.4) | 11 (33.3) | 23 (34.8) |
| >60 | 21 (63.6) | 22 (66.7) | 43 (65.2) |
| Sex, n (%) | |||
| Male | 15 (45.5) | 13 (39.4) | 28 (42.4) |
| Female | 18 (54.5) | 20 (60.6) | 38 (57.6) |
| Race, n (%) | |||
| White | 31 (93.9) | 33 (100.0) | 64 (97.0) |
| Others | 1 (3.0) | 0 | 1 (1.5) |
| Missing | 1 (3.0) | 0 | 1 (1.5) |
| Ann Arbor disease stage, n (%) | |||
| I | 2 (6.1) | 1 (3.0) | 3 (4.5) |
| II | 0 | 1 (3.0) | 1 (1.5) |
| III | 8 (24.2) | 7 (21.2) | 15 (22.7) |
| IV | 23 (69.7) | 24 (72.7) | 47 (71.2) |
| IPI risk score, n (%) | |||
| IPI 2 | 13 (39.4) | 11 (33.3) | 24 (36.4) |
| IPI 3 | 13 (39.4) | 16 (48.5) | 29 (43.9) |
| IPI 4 | 7 (21.2) | 4 (12.1) | 11 (16.7) |
| IPI 5 | 0 | 2 (6.1) | 2 (3.0) |
| ECOG PS, n (%) | |||
| 0 | 19 (57.6) | 12 (36.4) | 31 (47.0) |
| 1 | 12 (36.4) | 17 (51.5) | 29 (43.9) |
| 2 | 2 (6.1) | 4 (12.1) | 6 (9.1) |
| Preplanned radiotherapy, n (%) | |||
| Yes | 4 (12.1) | 3 (9.1) | 7 (10.6) |
| No | 29 (87.9) | 30 (90.9) | 59 (89.4) |
| Preplanned intrathecal chemotherapy, n (%) | |||
| Yes | 7 (21.2) | 4 (12.1) | 11 (16.7) |
| No | 26 (78.8) | 29 (87.9) | 55 (83.3) |
| Elevated LDH levels, n (%) | |||
| Yes | 23 (69.7) | 24 (72.7) | 47 (71.2) |
| No | 10 (30.3) | 9 (27.3) | 19 (28.8) |
| Stage III/IV disease, n (%) | |||
| Yes | 31 (93.9) | 31 (93.9) | 62 (93.9) |
| No | 2 (6.1) | 2 (6.1) | 4 (6.1) |
| Bulky disease, n (%) | |||
| Yes | 14 (42.4) | 15 (45.5) | 29 (43.9) |
| No | 19 (57.6) | 18 (54.5) | 37 (56.1) |
| COO, n (%)∗ | |||
| GCB | 18 (54.5) | 19 (57.6) | 37 (56.1) |
| Non-GCB | 12 (36.4) | 12 (36.4) | 24 (36.4) |
| Missing | 3 (9.1) | 2 (6.1) | 5 (7.5) |
| . | Arm T Tafasitamab + R-CHOP (n = 33) . | Arm T/L Tafasitamab + lenalidomide + R-CHOP (n = 33) . | Overall (n = 66) . |
|---|---|---|---|
| Median age (range), y | 66.0 (43-86) | 64.0 (20-79) | 64.5 (20-86) |
| Age categories (y), n (%) | |||
| ≤60 | 12 (36.4) | 11 (33.3) | 23 (34.8) |
| >60 | 21 (63.6) | 22 (66.7) | 43 (65.2) |
| Sex, n (%) | |||
| Male | 15 (45.5) | 13 (39.4) | 28 (42.4) |
| Female | 18 (54.5) | 20 (60.6) | 38 (57.6) |
| Race, n (%) | |||
| White | 31 (93.9) | 33 (100.0) | 64 (97.0) |
| Others | 1 (3.0) | 0 | 1 (1.5) |
| Missing | 1 (3.0) | 0 | 1 (1.5) |
| Ann Arbor disease stage, n (%) | |||
| I | 2 (6.1) | 1 (3.0) | 3 (4.5) |
| II | 0 | 1 (3.0) | 1 (1.5) |
| III | 8 (24.2) | 7 (21.2) | 15 (22.7) |
| IV | 23 (69.7) | 24 (72.7) | 47 (71.2) |
| IPI risk score, n (%) | |||
| IPI 2 | 13 (39.4) | 11 (33.3) | 24 (36.4) |
| IPI 3 | 13 (39.4) | 16 (48.5) | 29 (43.9) |
| IPI 4 | 7 (21.2) | 4 (12.1) | 11 (16.7) |
| IPI 5 | 0 | 2 (6.1) | 2 (3.0) |
| ECOG PS, n (%) | |||
| 0 | 19 (57.6) | 12 (36.4) | 31 (47.0) |
| 1 | 12 (36.4) | 17 (51.5) | 29 (43.9) |
| 2 | 2 (6.1) | 4 (12.1) | 6 (9.1) |
| Preplanned radiotherapy, n (%) | |||
| Yes | 4 (12.1) | 3 (9.1) | 7 (10.6) |
| No | 29 (87.9) | 30 (90.9) | 59 (89.4) |
| Preplanned intrathecal chemotherapy, n (%) | |||
| Yes | 7 (21.2) | 4 (12.1) | 11 (16.7) |
| No | 26 (78.8) | 29 (87.9) | 55 (83.3) |
| Elevated LDH levels, n (%) | |||
| Yes | 23 (69.7) | 24 (72.7) | 47 (71.2) |
| No | 10 (30.3) | 9 (27.3) | 19 (28.8) |
| Stage III/IV disease, n (%) | |||
| Yes | 31 (93.9) | 31 (93.9) | 62 (93.9) |
| No | 2 (6.1) | 2 (6.1) | 4 (6.1) |
| Bulky disease, n (%) | |||
| Yes | 14 (42.4) | 15 (45.5) | 29 (43.9) |
| No | 19 (57.6) | 18 (54.5) | 37 (56.1) |
| COO, n (%)∗ | |||
| GCB | 18 (54.5) | 19 (57.6) | 37 (56.1) |
| Non-GCB | 12 (36.4) | 12 (36.4) | 24 (36.4) |
| Missing | 3 (9.1) | 2 (6.1) | 5 (7.5) |
LDH, lactate dehydrogenase.
As assessed centrally using IHC-HANS algorithm; other testing is detailed in supplemental Material.